Red blood cell numbers increase due to increased erythropoietin levels.

An important example of such a complex protein is the hormone erythropoietin.

High blood pressure can develop during treatment with erythropoietin stimulators.

Erythropoietin is a hormone which controls red blood cell production.

To the researchers' surprise, erythropoietin did not improve cancer treatment or survival.

This is the most common reason that erythropoietin stimulators may not be effective.

No tests for the drug erythropoietin are in use in athletics.

Erythropoietin and iron therapy can be considered in cases of anemia.

For some conditions, such as chronic kidney disease, medicine called erythropoietin may be given.

Most people do not have problems with erythropoietin stimulators.

These patients usually do not respond to erythropoietin therapy.

But he said the suggestion that erythropoietin could interfere with cancer treatment was not borne out by the data.

"We do not have data that tumor progression is an issue as a result of erythropoietin treatment.

Both the European and American drugs are forms of the human protein erythropoietin.

Erythropoietin is used to treat people with anemia, due to critical illness.

Erythropoietin is an essential hormone for red cell production.

The developmental signal, also called a cytokine, is erythropoietin in this case.

Erythropoietin is needed to make red blood cells.

"We don't believe the erythropoietin protein is patentable," he said.

Iron studies show your level of iron, which is needed for erythropoietin to work the way it should.

If needed, red blood cell transfusions or erythropoietin can be used for management of anemia.

Treatment with erythropoietin stimulators may delay the need to start dialysis.

Erythropoietin has not been found to be effective to prevent or treat anemia in people with burns.

Erythropoietin, a genetically engineered drug, stimulates the body to produce more red cells.

Erythropoietin is produced in the kidneys and stimulates the production of red blood cells.

For some years, the drumbeat of concern about Epo has been growing in the medical community.

EPO is the most publicly known drug in this class.

Rather, some experts say, Epo may spur tumor growth.

Epo has a lot of potential uses and could provide a therapeutic answer for nervous system injury.

However, more studies need to be conducted to determine the optimal time and dosage for Epo treatment.

One EPO test looks at the size of red blood cells.

"EPO has polluted the world sports stage," she said in an interview.

EPO is also involved in the wound healing process.

The level of red blood cells in his system indicated EPO use.

EPO may also be an effective treatment for depression.

Epo has also been demonstrated to enhance nerve recovery after spinal trauma.

EPO is often used as a performance enhancing drug by professional cyclists.

EPO is the second genetically engineered drug known to be abused by athletes.

The urine test for EPO has come under dispute before.

That made it difficult or impossible to determine if EPO had been present.

A test for EPO was not available until 2000.

"We will likely have an EPO test, or close to one.

I've heard of guys with renal failure from taking EPO.

But the companies do seem to be working on these new aspects of EPO quietly.

EPO, which you mentioned earlier - it's for people who have chronic anemia.

Essentially, there are two ways to make the EPO protein.

EPO is something we don't need to see in horse racing."

Baseball did 500 tests for EPO in 2005, and no one noticed.

The EPO marks a huge step forward in victim rights.

We also did not find any side effect of EPO consistently reported among trials.

Eosinophil peroxidase is also partly responsible for tissue remodeling.

It is formed by eosinophil peroxidase.

The oxidizing compounds produced by eosinophil peroxidase have been implicated in the inflammatory pathology of several disease states, including asthma.

For example, although eosinophil peroxidase is able to oxidize chloride, it preferentially oxidizes bromide.

Major basic protein, eosinophil peroxidase, and eosinophil cationic protein are toxic to many tissues.

Eosinophil peroxidase is a haloperoxidase enzyme that in humans is encoded by the EPX gene.

For example, eosinophil peroxidase appears to prefer bromide over chloride, yet is not considered a bromoperoxidase because it is able to use chloride.

Eosinophil peroxidase is a haloperoxidase that preferentially uses bromide over chloride for this purpose, generating hypobromite (hypobromous acid).

Eosinophil peroxidase forms reactive oxygen species and reactive nitrogen intermediates that promote oxidative stress in the target, causing cell death by apoptosis and necrosis.

The compound is generated in warm-blooded vertebrate organisms especially by eosinophils, which produce it by the action of eosinophil peroxidase, an enzyme which preferentially uses bromide.

Heme l is the derivative of heme B which is covalently attached to the protein of lactoperoxidase, eosinophil peroxidase, and thyroid peroxidase.

The recruited eosinophils will degranulate releasing a number of cytotoxic molecules (including Major Basic Protein and eosinophil peroxidase) as well as produce a number of cytokines such as IL-5.

Heme l is one important characteristic of animal peroxidases; plant peroxidases incorporate heme B. Lactoperoxidase and eosinophil peroxidase are protective enzymes responsible for the destruction of invading bacteria and virus.

The staining is concentrated in small granules within the cellular cytoplasm, which contain many chemical mediators, such as histamines and proteins such as eosinophil peroxidase, ribonuclease (RNase), deoxyribonucleases, lipase, plasminogen, and major basic protein.

In the presence of HO formed by the eosinophil, and either chloride or bromide ions, eosinophil peroxidase provides a potent mechanism by which eosinophils kill multicellular parasites (such as, for example, the nematode worms involved in filariasis); and also certain bacteria (such as tuberculosis bacteria).

It is likely to be administered by the European Patent Office.

I would like to make it clear once again that the European Patent Office does not have a court.

The decision by the European Patent Office will be tremendously important.

The European Patent Office does issue patents in this area.

The European Patent Office has issued a press statement to that effect.

That is the reason why the European Patent Office uses more than one expert.

In 1984, he started a career of international civil servant at the European Patent Office.

Europe and the European Patent Office in fact have a very high level of inventiveness.

We believe that sustaining the existing system inside the European Patent Office is important.

This means lodging a firm objection with the European Patent Office.

A video at the European Patent Office explains the nomination and the invention.

The European Patent Office does not make decisions on infringement matters.

I would be interested to know what progress is being made and whether you really are resolving the language issue in the European Patent Office.

I should also like to add that the language regime of the European Patent Office cannot be decided by the Community alone.

Furthermore, countries may still grant their own national patents independently of the European Patent Office.

May I point out that the European Patent Office is not a Community agency.

The fact is, moreover, that the European Patent Office has extended the scope of its activities slowly and gradually.

The European Patent Office has already demonstrated its own ability to do damage in the field of software patentability.

The agreement is modeled after the treaty that established the European patent office in Munich, Germany.

Criticism is also expected from within Europe, not least from the European Patent Office.

We'd have no chance in the United Kingdom, or the European Patent Office.

Therefore, I cannot give you authoritative information on the actions of the European Patent Office in this particular case.

What has happened in this connection is therefore a flagrant breach of the European Patent Office' s own rules.

That directive is due to be implemented by the end of this month and it should also bind the European Patent Office.

With regard to the language regime used at the European Patent Office, the text simply notes that translation costs must be limited.